Thalia raises €3.1M and buys Sanmirna
Thalia Therapeutics raised €3.1M and acquired Sanmirna Therapeutics to expand its RNA therapeutics pipeline.
RNA therapeutics are still expanding beyond the biggest biotech platforms. Thalia Therapeutics is using fresh funding and an acquisition to move deeper into clinical-stage drug development.
What happened
Thalia Therapeutics, a UK biotech developing RNA-based therapeutics, raised €3.1M and acquired Sanmirna Therapeutics.
The acquisition adds miRisten, a clinical-stage microRNA therapeutic candidate for acute myeloid leukaemia, to Thalia’s pipeline.
Why it matters
This is a biotech platform signal.
The deal moves Thalia toward becoming a clinical-stage RNA therapeutics company and expands its pipeline across oncology and cardiovascular disease.
The bigger picture
Biotech startups are increasingly combining financing with targeted acquisitions to strengthen pipelines faster. For RNA therapeutics, platform credibility often depends on moving from scientific promise into clinical-stage assets.